Pharmaceutical Technology Editors

The companies will use GeoVax’s vaccine technology to develop malaria vaccine candidates.

Sartorius Stedim Biotech (SSB) and Novasep will partner to develop systems for membrane chromatography using Novasep’s BioSC platform and SSB’s single-use technology.

The acquisition will establish a clinical pipeline for Biogen of gene-therapy candidates in ophthalmology.

The FDA commissioner plans to leave the agency in April.

FDA guidance on quality considerations for continuous manufacturing should help advance implementation by providing clarity and giving companies more confidence to make investments in the new technology.

The Tandem 4.0 augmented reality-enhanced collaboration tool from Apprentice.io has a new user experience and user interface design.

AST will unveil its multi-format robotic filling system, the GENiSYS R, at INTERPHEX.

The Marchesini Group will introduce the CMP pharma inspection system to the US market at INTERPHEX 2019.

The company is voluntarily recalling four lots of Drospirenone and Ethinyl Estradiol Tablets, USP because of the possibility they may contain defective blister packs and incorrect tablet arrangements.

A new report that has been published prior to CPhI Japan has stated that there will be rapid growth in the Japanese pharma market during 2019.

Aclaris Therapeutics has been granted a marketing approval from the Swedish Medical Products Agency for ESKATA.

The ABPI has responded to the UK government’s recently published plans on improvements to services for people with rare diseases

GHO Capital, a European specialist investor in healthcare, announced its acquisition of Sterling Pharma Solutions, which specializes in complex and difficult-to-manufacture APIs.

STA Pharmaceuticals and BioLingus have announced the formation of an exclusive technology and marketing collaboration for sublingual delivery.

Abbott and Novo Nordisk have entered into a non-exclusive partnership aimed at providing an integrated digital solution for diabetic patients using insulin,

Oxford Gene Technology (OGT) has revealed it is expanding its operations with a new facility in Cambridge, UK, to house its expanding Cytocell brand.

The technology uses a silica nanoparticle to deliver vaccines and cancer treatments.

Recipharm has received ISO 45001 certification for its Wasserberg facility in Germany as a result of the facility’s program to enhance sustainability and safety.

The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac partner to develop a transportable mRNA vaccine manufacturing platform.

A project conducted by research institute CEA-Leti led to the development of a new HIV vaccine approach based on engineered lipid nanoparticles.

LabVantage Solutions’ LabVantage 8.4 is the latest version of the company’s comprehensive laboratory information management system.

HORIBA’s new analytical microscope simultaneously performs elemental analysis and optical observation without destroying samples.

The TSKgel FcR-IIIA-NPR HPLC column from Tosoh Bioscience is a FcRγ affinity chromatography analysis column suited for the analysis of immunoglobulin G glycoforms.

The $4.3-billion acquisition is expected to strengthen Roche’s gene therapy pipeline.

The $21.4-billion acquisition will create stand-alone business within Danaher’s life-sciences portfolio.

A draft guidance document provides recommendations for submitting bioavailability information in investigational new drug and new drug applications.

Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg after NDEA is found in finished product manufactured with API made by Hetero Labs Limited.

The Pharmacovigilance Risk Assessment Committee of the European Medicines Agency has issued a recommendation for the suspension of fenspiride medicines across the whole of the European Union.

ACG Group highlighted its expanded footprint in Brazil through the launch of a new capsules manufacturing plant in Pouso Alegre-Minas Gerais.

Valitacell and Solentim, have announced a collaboration aimed at the acceleration of discovery and development of biologic drugs and advanced cell therapies.